Royalty Pharma plc Payments to Acquire Debt Securities, Available-for-sale
Royalty Pharma plc (RPRX) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $100.00M.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for fiscal 2025 was $175.00M, a 16.67% increase from fiscal 2024.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for fiscal 2024 was $150.00M.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Royalty Pharma plc payments to acquire debt securities, available-for-sale for fiscal 2022 was $479.56M, a 580.80% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | ||||
| 2025-12-31 | $100.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $100.00M derived: sum of 2 quarters · filed 2026-02-11 | $175.00M 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $75.00M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $75.00M 10-Q · filed 2026-08-05 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $150.00M 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $150.00M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $150.00M 10-Q · filed 2025-08-06 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $85.82M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $85.82M derived: sum of 3 quarters · filed 2025-02-12 | $400.40M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $85.82M derived: sum of 2 quarters · filed 2025-02-12 | $400.40M derived: sum of 3 quarters · filed 2025-02-12 | $414.98M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $85.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $400.40M derived: sum of 2 quarters · filed 2025-02-12 | $414.98M derived: sum of 3 quarters · filed 2025-02-12 | $479.56M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $314.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $329.16M derived: sum of 2 quarters · filed 2023-11-08 | $393.74M 10-Q · filed 2023-11-08 | $411.42M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | $14.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $79.16M 10-Q · filed 2023-08-08 | $96.84M derived: sum of 3 quarters · filed 2024-02-15 | $114.43M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | $64.58M 10-Q · filed 2023-05-09 | $82.27M derived: sum of 2 quarters · filed 2024-02-15 | $99.85M derived: sum of 3 quarters · filed 2024-02-15 | $117.44M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $35.27M derived: sum of 2 quarters · filed 2024-02-15 | $52.86M derived: sum of 3 quarters · filed 2024-02-15 | $70.44M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $17.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $35.17M derived: sum of 2 quarters · filed 2022-11-08 | $52.76M 10-Q · filed 2022-11-08 | $52.76M derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-06-30 | $17.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $35.17M 10-Q · filed 2022-08-04 | $35.17M derived: sum of 3 quarters · filed 2023-02-15 | $35.17M derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-03-31 | $17.59M 10-Q · filed 2022-05-05 | $17.59M derived: sum of 2 quarters · filed 2023-02-15 | $17.59M derived: sum of 3 quarters · filed 2023-02-15 | $17.59M derived: sum of 4 quarters · filed 2023-02-15 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | $0.00 10-K · filed 2023-02-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-02-15 | $4.00K derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $4.00K derived: sum of 3 quarters · filed 2022-02-15 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $4.00K derived: sum of 2 quarters · filed 2022-02-15 | $125.12M 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $125.12M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $125.12M 10-Q · filed 2020-08-12 | ||||
| 2019-04-05 | $125.00M 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |